The feasibility of sentinel lymph node biopsy after axillary lymph node clinical complete response
10.3760/cma.j.issn.1008-1372.2019.01.016
- VernacularTitle:新辅助化疗腋窝淋巴结临床完全缓解乳腺癌患者前哨淋巴结活检的可行性分析
- Author:
Wenjing ZHU
1
;
Qiu LIANG
Author Information
1. 厦门大学附属中山医院乳腺外科 361004
- Keywords:
Breast neoplasms;
Sentinel lymph node biopsy;
Antineoplastic combined chemotherapy protocols;
Feasibility studies
- From:
Journal of Chinese Physician
2019;21(1):59-63
- CountryChina
- Language:Chinese
-
Abstract:
Objective The use of sentinel lymph node biopsy (SLNB) following neoadjuvant chemotherapy (NAC) in patients presenting with clinically positive lymph nodes remains controversial.This study is aimed to invest if it is feasible to perform SLNB after NAC in case that axillary lymph nodes turned to clinical negative.Methods A computer-aided search of the literature regarding SLNB in clinically nodepositive breast cancer treated with NAC was carried out to identify the false negative rate (FNR),sentinel lymph node identification rate (IR).Results 16 articles were used in the analysis yielding 1 579 patients.The pooled estimate of FNR,IR,sensitivity and overall accurancy was 13.6％,91％,85.7％,and 92.8％,respectively.Conclusions SLNB after NAC in lymph node-positive patients,whose axillary lymph node was clinical negative after NAC,results in reasonably IR,but FNR was still high to be accepted.More refined patient selection and optimal techniques are expected to lower the FNR in this patient population.
